Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
出版年份 2013 全文链接
标题
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 16, Issue 1, Pages 38-47
出版商
Wiley
发表日期
2013-07-06
DOI
10.1111/dom.12175
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
- (2012) Matteo Monami et al. Experimental Diabetes Research
- Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
- (2011) Nicole R Pinelli et al. ANNALS OF PHARMACOTHERAPY
- Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
- (2011) B. Vergès et al. DIABETES & METABOLISM
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
- (2011) Steven P Marso et al. Diabetes & Vascular Disease Research
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
- (2011) Matteo Monami et al. Experimental Diabetes Research
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2009) Matteo Monami et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) E. Mannucci et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
- (2008) E. Mannucci et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started